These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 19416226)
41. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R; Circ Heart Fail; 2008 May; 1(1):9-16. PubMed ID: 19808265 [TBL] [Abstract][Full Text] [Related]
43. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. Melenovsky V; Al-Hiti H; Kazdova L; Jabor A; Syrovatka P; Malek I; Kettner J; Kautzner J J Am Coll Cardiol; 2009 Aug; 54(7):595-600. PubMed ID: 19660688 [TBL] [Abstract][Full Text] [Related]
44. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M; Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414 [TBL] [Abstract][Full Text] [Related]
45. Relaxin-2 may offer therapeutic advantages in end-stage heart failure. Zhao Z; Liu T; Li G Int J Cardiol; 2012 Jun; 157(3):432-3. PubMed ID: 22541981 [No Abstract] [Full Text] [Related]
46. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. Tsukamoto O; Fujita M; Kato M; Yamazaki S; Asano Y; Ogai A; Okazaki H; Asai M; Nagamachi Y; Maeda N; Shintani Y; Minamino T; Asakura M; Kishimoto I; Funahashi T; Tomoike H; Kitakaze M J Am Coll Cardiol; 2009 Jun; 53(22):2070-7. PubMed ID: 19477358 [TBL] [Abstract][Full Text] [Related]
47. Relaxin: review of biology and potential role in treating heart failure. Teichman SL; Unemori E; Teerlink JR; Cotter G; Metra M Curr Heart Fail Rep; 2010 Jun; 7(2):75-82. PubMed ID: 20424993 [TBL] [Abstract][Full Text] [Related]
49. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Varr BC; Maurer MS Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571 [TBL] [Abstract][Full Text] [Related]
50. Recombinant human relaxin (rhRLX) modifies systemic arterial properties in conscious rats irrespective of gender, but in a biphasic fashion. Debrah DO; Conrad KP; Novak J; Danielson LA; Shroff SG Ann N Y Acad Sci; 2005 May; 1041():155-62. PubMed ID: 15956701 [TBL] [Abstract][Full Text] [Related]
51. Reversal of cardiac fibrosis and related dysfunction by relaxin. Du XJ; Xu Q; Lekgabe E; Gao XM; Kiriazis H; Moore XL; Dart AM; Tregear GW; Bathgate RA; Samuel CS Ann N Y Acad Sci; 2009 Apr; 1160():278-84. PubMed ID: 19416203 [TBL] [Abstract][Full Text] [Related]
52. RELAX-AHF: rising from the doldrums in acute heart failure. Konstam MA Lancet; 2013 Jan; 381(9860):5-6. PubMed ID: 23141815 [No Abstract] [Full Text] [Related]
53. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. Smith MC; Danielson LA; Conrad KP; Davison JM J Am Soc Nephrol; 2006 Nov; 17(11):3192-7. PubMed ID: 17035617 [TBL] [Abstract][Full Text] [Related]
55. Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs. Muppidi A; Lee SJ; Hsu CH; Zou H; Lee C; Pflimlin E; Mahankali M; Yang P; Chao E; Ahmad I; Crameri A; Wang D; Woods A; Shen W Bioconjug Chem; 2019 Jan; 30(1):83-89. PubMed ID: 30543420 [TBL] [Abstract][Full Text] [Related]
56. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension. Chunduri P; Patel SA; Levick SP Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372 [TBL] [Abstract][Full Text] [Related]
57. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Verdino P; Lee SL; Cooper FN; Cottle SR; Grealish PF; Hu CC; Meyer CM; Lin J; Copeland V; Porter G; Schroeder RL; Thompson TD; Porras LL; Dey A; Zhang HY; Beebe EC; Matkovich SJ; Coskun T; Balciunas AM; Ferrante A; Siegel R; Malherbe L; Bivi N; Paavola CD; Hansen RJ; Abernathy MM; Nwosu SO; Carr MC; Heuer JG; Wang X Br J Pharmacol; 2023 Aug; 180(15):1965-1980. PubMed ID: 36780899 [TBL] [Abstract][Full Text] [Related]
58. Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. Greene SJ; Gheorghiade M J Am Coll Cardiol; 2014 Oct; 64(15):1599-601. PubMed ID: 25301464 [No Abstract] [Full Text] [Related]
59. Relaxin: not a health hazard but a promising therapeutic opportunity. Bigazzi M; Bani D; Dschietzig T Bone; 2010 Oct; 47(4):832-3; author reply 834. PubMed ID: 20488260 [No Abstract] [Full Text] [Related]
60. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. Milo-Cotter O; Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Edwards C; Weatherley BD; Greenberg B; Filippatos G; Unemori E; Teichman SL; Cotter G Cardiology; 2010; 117(3):190-6. PubMed ID: 21088400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]